Literature DB >> 1824252

Inhibition of human erythroid colony-forming units by gamma interferon can be corrected by recombinant human erythropoietin.

R T Means1, S B Krantz.   

Abstract

Tumor necrosis factor (TNF), interleukin-1 (IL-1), and gamma interferon (gamma IFN) inhibit erythropoiesis in vivo and in vitro, and have been implicated in the pathogenesis of the anemia of chronic disease. Anemia in patients with rheumatoid arthritis and in animals exposed chronically to IL-1 and TNF can be corrected by the administration of recombinant erythropoietin (Epo). We exposed highly purified human erythroid colony-forming units (CFU-E) cultured from peripheral blood burst-forming units-erythroid (BFU-E) and unpurified human marrow CFU-E to recombinant human gamma IFN and showed inhibition of colony formation in vitro. This inhibition was reversed by increased concentrations of Epo. The mechanisms by which this effect occurs are unknown at present. Epo may cause a downregulation of gamma IFN receptor expression on CFU-E or, alternatively, gamma IFN may cause a downregulation of Epo receptor expression. A full understanding of these mechanisms awaits a more complete comprehension of the regulation of erythropoiesis; however, the effect of Epo in vitro is similar to its ability to correct the anemia of chronic disease in vivo.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1824252

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  22 in total

1.  Anaemia in systemic lupus erythematosus: aetiological profile and the role of erythropoietin.

Authors:  M Voulgarelis; S I Kokori; J P Ioannidis; A G Tzioufas; D Kyriaki; H M Moutsopoulos
Journal:  Ann Rheum Dis       Date:  2000-03       Impact factor: 19.103

Review 2.  Anemia of inflammation.

Authors:  Elizabeta Nemeth; Tomas Ganz
Journal:  Hematol Oncol Clin North Am       Date:  2014-05-28       Impact factor: 3.722

3.  IFN-γ directly inhibits the activity of erythropoietin in human erythroid progenitors.

Authors:  Daisuke Araki; Luigi J Alvarado; Heather D Huntsman; Richard H Smith; Andre Larochelle
Journal:  Blood Cells Mol Dis       Date:  2020-08-21       Impact factor: 3.039

Review 4.  Anaemia in inflammatory rheumatic diseases.

Authors:  Günter Weiss; Georg Schett
Journal:  Nat Rev Rheumatol       Date:  2012-11-13       Impact factor: 20.543

Review 5.  The erythroblastic island as an emerging paradigm in the anemia of inflammation.

Authors:  Jimmy Hom; Brian M Dulmovits; Narla Mohandas; Lionel Blanc
Journal:  Immunol Res       Date:  2015-12       Impact factor: 2.829

Review 6.  Anaemia in systemic lupus erythematosus: from pathophysiology to clinical assessment.

Authors:  S Giannouli; M Voulgarelis; P D Ziakas; A G Tzioufas
Journal:  Ann Rheum Dis       Date:  2005-08-03       Impact factor: 19.103

7.  Cisplatin-associated anemia: an erythropoietin deficiency syndrome.

Authors:  P A Wood; W J Hrushesky
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

Review 8.  Iron, anaemia, and inflammatory bowel diseases.

Authors:  C Gasche; M C E Lomer; I Cavill; G Weiss
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

9.  Polymorphisms in two genes, IL-1B and ACE, are associated with erythropoietin resistance in Korean patients on maintenance hemodialysis.

Authors:  Kyung Hwan Jeong; Tae Won Lee; Chun Gyoo Ihm; Sang Ho Lee; Ju Young Moon
Journal:  Exp Mol Med       Date:  2008-04-30       Impact factor: 8.718

10.  R-h-erythropoietin counteracts the inhibition of in vitro erythropoiesis by tumour necrosis factor alpha in patients with rheumatoid arthritis.

Authors:  M Jongen-Lavrencic; H R Peeters; B Backx; I P Touw; G Vreugdenhil; A J Swaak
Journal:  Rheumatol Int       Date:  1994       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.